THE RELATIONSHIP OF QUANTITATIVE EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NONSMALL CELL LUNG-CANCER TO LONG-TERM SURVIVAL

被引:194
作者
VEALE, D
KERR, N
GIBSON, GJ
KELLY, PJ
HARRIS, AL
机构
[1] CHURCHILL HOSP,IMPERIAL CANC RES FUND CLIN ONCOL UNIT,OXFORD OX3 7LJ,ENGLAND
[2] FREEMAN RD HOSP,DEPT RESP MED,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND
[3] UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
关键词
D O I
10.1038/bjc.1993.306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased expression of epidermal growth factor receptor (EGFr) has been reported in non small cell lung cancers (NSCLC) when compared to normal lung. We have examined post-operative survival in 19 surgically treated patients with NSCLC who had full characterisation of EGFr on primary tumour membrane preparations from resection specimens. There were ten squamous, seven adeno and two large cell carcinomas. The median concentration of high affinity sites was 31 fmol per mg of protein (4-1532) and the median dissociation constant (Kd) of these high affinity sites was 2.3 x 10(-10) per mol (1.2-30 x 10(-10)). Seven patients survived over 5 years. Twelve patients died between 8.5 and 55 months from the time of surgery. When > 5 year survivors were compared to non-survivors there was no difference as regards tumour size or stage, or as regards age or sex. The survivors had a median concentration of high affinity EGFr sites of 16.1 fmol mg-1 protein compared to a median concentration of 68.6 fmol mg-1 protein in the non-survivors (P = 0.01 Wilcoxon test). No long term survivor had > 35 fmol mg-1 protein of receptor. Thus EGFr quantitation may give independent prognostic information in NSCLC and help to select patients for adjuvant therapy after surgery. These results need confirmation in a larger prospective study.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 28 条
  • [1] Altman, 1991, PRACTICAL STATICTS M
  • [2] BENNETT JP, 1978, NEUROTRANSMITTER REC, P57
  • [3] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [4] THE BIOCHEMISTRY AND PHYSIOLOGY OF THE RECEPTOR-KINASE FOR EPIDERMAL GROWTH-FACTOR
    CARPENTER, G
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1983, 31 (01) : 1 - 19
  • [5] COHEN S, 1963, J INVEST DERMATOL, V40, P1
  • [6] DNA ANALYSIS BY FLOW-CYTOMETRY IN NONSMALL CELL LUNG-CANCER - RELATIONSHIP TO EPIDERMAL GROWTH-FACTOR RECEPTOR, HISTOLOGY, TUMOR STAGE AND SURVIVAL
    DAZZI, H
    THATCHER, N
    HASLETON, PS
    SWINDELL, R
    [J]. RESPIRATORY MEDICINE, 1990, 84 (03) : 217 - 223
  • [7] EPIDERMAL GROWTH-FACTOR RECEPTOR IN LUNG MALIGNANCIES - COMPARISON BETWEEN CANCER AND NORMAL TISSUE
    DITTADI, R
    GION, M
    PAGAN, V
    BRAZZALE, A
    DELMASCHIO, O
    BARGOSSI, A
    BUSETTO, A
    BRUSCAGNIN, G
    [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (04) : 741 - 744
  • [8] SIMPLE, SPECIFIC, RADIOISOTOPIC ASSAY FOR 5'-NUCLEOTIDASE
    GENTRY, MK
    OLSSON, RA
    [J]. ANALYTICAL BIOCHEMISTRY, 1975, 64 (02) : 624 - 627
  • [9] HENDLER F, 1988, J CELL BIOCHEM, V105, pSA12
  • [10] EPIDERMAL GROWTH-FACTOR RECEPTOR IN OVARIAN-TUMORS - CORRELATION OF IMMUNOHISTOCHEMISTRY WITH LIGAND-BINDING ASSAY
    HENZENLOGMANS, SC
    BERNS, EMJJ
    KLIJN, JGM
    VANDERBURG, MEL
    FOEKENS, JA
    [J]. BRITISH JOURNAL OF CANCER, 1992, 66 (06) : 1015 - 1021